Medical News

RSS

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Infinity Pharmaceuticals, Inc. today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940.

26 Oct 2010

miRagen and CU enter agreement on miRNA therapeutics discovery and development

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and the University of Colorado (CU) announced today that they have entered into sponsored research and licensing agreements to collaborate on miRNA therapeutics discovery and development.

26 Oct 2010

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Agile Therapeutics announced results today from a Phase 2 clinical study of AG200-15, Agile's weekly contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). According to the clinical findings, AG200-15 provides a low daily dose of estrogen equivalent to 30 micrograms EE, similar to that in low-dose, oral contraceptive (OC) pills.

26 Oct 2010

ACS My Medicare Advocate helps retirees chart Medicare decision process

Retirees will find it easier than ever to navigate the often confusing maze of Medicare enrollment with the introduction of My Medicare Advocate by Affiliated Computer Services, Inc., A Xerox Company.

26 Oct 2010

Mundus studies potential for VTOL UAV against Malaria

Mundus Group Inc., studies potential for VTOL UAV to provide increased capabilities in fight against Malaria and disease spread through mosquitoes with precision aerial laser eradication treatments.

26 Oct 2010

Cryo-Cell formalizes industry-exclusive agreement with MedTech For Solutions GPO

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and global stem cell innovators, today announced at the annual meeting of the American Society of Reproductive Medicine (ASRM) that the Company has formalized an industry-exclusive agreement with MedTech For Solutions, Inc., a Group Purchasing Organization (GPO) representing a member network of 115 practices specializing in reproductive medicine, which operates in conjunction with The Broadlane Group.

26 Oct 2010

New heart and vascular clinic to implement Streamline Health's HIM Suite of document workflow solutions

Streamline Health Solutions, Inc. a leading provider of document workflow solutions for hospitals, today announced that one of the country's leading healthcare organizations expects to open a new facility utilizing Streamline Health's Suite of Health Information Management document workflow solutions.

26 Oct 2010

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a 4 week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

26 Oct 2010

Shire receives Paragraph IV Notice Letter from Watson for INTUNIV tablet

Shire plc , the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 4 mg guanfacine hydrochloride extended release tablet, INTUNIV.

26 Oct 2010

MiMedx third-quarter net loss decreases to $2.9 million

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today its results for the third quarter ended September 30, 2010.

26 Oct 2010

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.

26 Oct 2010

LCA-Vision third quarter net loss decreases to $8.4 million

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operational results for the three and nine months ended September 30, 2010.

26 Oct 2010

Techne Corporation 2011 first quarter net earnings decreases 1.5% to $26.4 million

Techne Corporation's consolidated net earnings for the quarter ended September 30, 2010 decreased 1.5% to $26.4 million or $.71 per diluted share compared with $26.8 million or $.72 per diluted share for the quarter ended September 30, 2009.

From BiosPacific, Inc. 26 Oct 2010

PURE Bioscience raises $2.376M through unregistered private placement

PURE Bioscience, creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that it has sold $2.376 million of its common stock in an unregistered private placement solely to non-affiliated accredited investors.

26 Oct 2010

Racial disparities among children with frequent ear infections can influence access to health care resources

Ear infections are one of the most common health problems for children, with most kids experiencing at least one by their third birthday. Annual costs in the United States alone are in the billions of dollars.

26 Oct 2010

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Compugen Ltd. today reported financial results for the third quarter ending September 30, 2010.

26 Oct 2010

Amedisys 2010 third quarter Net service revenue increases 4.2% to $404.7 million

Amedisys, Inc. a leading home health and hospice company, today reported its financial results for the three and nine-month periods ended September 30, 2010.

26 Oct 2010

First Edition: October 26, 2010

In today's headlines, more reports from the campaign trail -- highlighting how tempers and politics continue to flare around health overhaul issues.

26 Oct 2010

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Biogen Idec Inc. a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its third quarter 2010 results.

26 Oct 2010

New findings could deliver low-cost method to extract anticancer compound

A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests. Researchers have isolated and grown stem cells from a yew tree whose bark is a natural source of the anticancer compound paclitaxel. The development could enable the compound to be produced on a commercial scale at low cost, with no harmful by-products.

26 Oct 2010

Medical News

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

miRagen and CU enter agreement on miRNA therapeutics discovery and development

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

ACS My Medicare Advocate helps retirees chart Medicare decision process

Mundus studies potential for VTOL UAV against Malaria

Cryo-Cell formalizes industry-exclusive agreement with MedTech For Solutions GPO

New heart and vascular clinic to implement Streamline Health's HIM Suite of document workflow solutions

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

Shire receives Paragraph IV Notice Letter from Watson for INTUNIV tablet

MiMedx third-quarter net loss decreases to $2.9 million

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

LCA-Vision third quarter net loss decreases to $8.4 million

Techne Corporation 2011 first quarter net earnings decreases 1.5% to $26.4 million

PURE Bioscience raises $2.376M through unregistered private placement

Racial disparities among children with frequent ear infections can influence access to health care resources

Compugen 2010 third quarter net loss decreases to $1.6 million from $1.9 million

Amedisys 2010 third quarter Net service revenue increases 4.2% to $404.7 million

First Edition: October 26, 2010

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

New findings could deliver low-cost method to extract anticancer compound

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News